Please rotate your device

GET PROPEL

Stay Informed

You are leaving the HCP website

You are being directed to a third-party website. Please note that this third-party website is not controlled by PROPELOpens.com.

Thank you for visiting our site.

Continue
The first real-world evidence analysis on the impact of the PROPEL family of implants in CRS patients
CMR Publication

The use of PROPEL following sinus surgery may result in payer savings from reduced healthcare resource utilization.

Learn More

STRENGTHEN YOUR SINUS SURGERY ARMAMENTARIUM WITH THE PROPEL FAMILY OF IMPLANTS

The PROPEL family of implants offers 3 steroid-eluting implants under one brand, allowing ENTs to select the best option that conforms to the anatomical needs of their patients1-3

learn more learn more learn more

MAXILLARY
SINUS

FRONTAL
SINUS

ETHMOID
SINUS

ethmoid sinus

For ethmoid sinus1

frontal sinus ethmoid sinus

For ethmoid sinus and
frontal sinus opening2

frontal sinus maxillary sinus

For sinus ostia:
frontal and maxillary3

Learn more about the benefits of PROPEL implants after sinus surgery

ARM YOURSELF WITH THE PROPEL FAMILY OF IMPLANTS, AN INNOVATION IN SINUS TECHNOLOGY

PROPEL is the FIRST and ONLY PMA-approved steroid-eluting sinus implant4

OPENS + DELIVERS

PROPEL keeps the sinuses open while releasing MF

PROPEL implants feature an innovative 2-in-1 mechanism that opens the sinuses while delivering mometasone furoate (MF), a potent corticosteroid, directly where it is needed1-3

+OPENS the sinus cavity

  • Self-expanding design that opens and supports the sinus cavity1

  • Non-obstructive design allows for sinus mucociliary clearance and the delivery of topical rinses1

  • Dissolvable frame bio-absorbs over 30-45 days after placement as the sinus cavity heals11

+DELIVERS MF locally

  • Delivers 370 μg of MF over 30 days*

  • MF present in the sinus mucosal tissue for up to 60 days5*

*Pre-clinical animal data.

Mometasone furoate delivers the ideal combination of potency and safety

Drug characteristics comparison6-9
Topical
Corticosteroid		 Lipophilicity6* Potency7†
(Receptor Affinity)		 Systemic
Bioavailability8‡
Dexamethasone Very Low (<1.0)9 Very Low (100) High (76%)
Triamcinolone (Kenalog) Low (1.0) Low (233) Medium (46%)
Budesonide Low (1.6) Intermediate (935) Medium (34%)
Mometasone furoate High (20.0) High (2300) Very Low (<1%)

*Lipophilicity numbers normalized relative to triamcinolone acetonide.

†As measured by relative receptor binding affinity compared to dexamethasone, which is set to a value of 100. Higher values designate greater potency.

‡As measured by plasma concentration of drug from intranasal vs. intravenous route.

Mometasone furoate was selected for use in PROPEL implants for its optimal sinonasal drug characteristics10:

Highly lipophilic
Readily absorbs into tissue

Targeted and potent
High glucocorticoid receptor affinity

Low systemic bioavailability
Minimizes systemic effects

PROPEL implants are clinically proven to maintain patency and improve patient outcomes following ESS by targeting inflammation, the underlying cause of chronic rhinosinusitis

YOUR PATIENT
+
PROPEL
=
IMPROVED
OUTCOMES

GET PROPEL

Stay Informed

This site is intended for healthcare professionals in the United States

Instructions for Use:

PROPEL PROPEL MINI PROPEL MINI WITH SDS PROPEL CONTOUR

Instructions for Use (EU):

PROPEL PROPEL MINI PROPEL CONTOUR
Stay Informed

References

  1. PROPEL [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2013.
  2. PROPEL Mini [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
  3. PROPEL Contour [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
  4. Food and Drug Administration. Approval Order. https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100044S018A.pdf. Accessed June 28, 2019.
  5. Li PM, Downie D, Hwang PH. Controlled steroid delivery via bioabsorbable stent: safety and performance in a rabbit model. Am J Rhinol Allergy. 2009;23(6):591-596.
  6. Lemke T, Williams D, Roche V, Zito SW, eds. Foye’s Principles of Medicinal Chemistry. 6th ed. Balitmore, MD: Lippincott Williams & Wilkins; 2008.
  7. Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1(4):356-363.
  8. Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22(1):1-12.
  9. PubChem. Dexamethasone. https://pubchem.ncbi.nlm.nih.gov/compound/Dexamethasone. Accessed June 28, 2019.
  10. Hochhaus G. Pharmacokinetic/pharmacodynamic profile ofmometasone furoate nasal spray: potential effects on clinical safety and efficacy. Clin Ther. 2008;30(1):1-13.
  11. MurrAH,et al. Int Forum Allergy Rhinol. 2011;1:23–32. REF-10007

The PROPEL sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with confirmed hypersensitivity or intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.IntersectENT.com/technologies/. Rx only.

©2022 Intersect ENT, Inc. All rights reserved. Intersect ENT and PROPEL are registered trademarks of Intersect ENT, Inc. in the United States and other countries. MPM-11549 Rev 7.0

The above-identified implants, delivery systems, and/or the use of the above-identified implants/delivery systems in a method may be covered by one or more U.S. and/foreign patents, found at intersectent.com/patents.